The M&A practice at Covington & Burling LLP has a strong track record of acting for blue-chip clients from the life sciences, technology, and energy sectors. The group offers a multidisciplinary approach, drawing on the strength of its foreign direct investment, regulatory, and IP departments, among others, to support client needs. European corporate head Gregor Frizzell concentrates on cross-border mergers and acquisitions, as well as joint ventures. He has particular expertise in leading on transactions with strong IP and licensing elements. Specialising in the technology, life sciences, and consumer goods sectors, Louise Nash is well regarded for her work on complex cross-border deals on behalf of global companies. Paul Claydon is recommended for his deep experience advising on public and private M&A in the life sciences sector. Other notable names in the group include James Gubbins and James Halstead.
Key clients
- AbbVie, Inc.
- AstraZeneca
Work highlights
- Advised Ergomed in its £703.1 million sale to funds advised by Permira Advisers.
- Advised Novartis in its up to $2.5 billion sale of part of its portfolio of eye products to Bausch + Lomb Corp.